Physician profile
Jerry D Kennett
NPI 1851383145
$1,200.94
in general payments reported to CMS, 2019-2025
19 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.14 · 2020: $49.27 · 2022: $104 · 2023: $350 · 2024: $345 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $168.34 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $131.77 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $113.21 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $96.45 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $77.26 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $74.42 | 2024-2025 | Wegovy |
| Abbott Laboratories | $72.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.24 | 2023-2024 | Verquvo |
| Pfizer INC. | $57.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.18 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $50.96 | 2024 | |
| Acist Medical Systems, INC. | $49.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.30 | 2023-2025 | Jardiance |
| Abiomed | $41.76 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $32.89 | 2022-2024 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.09 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $18.84 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Boston Scientific Corporation | $14.31 | 2024 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Kennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.